Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study of the Efficacy and Safety of ALV003 Treatment in Symptomatic Celiac Disease Patients Maintained on a Gluten-Free Diet

NCT01917630 is registered in ClinicalTrials.gov with Alvine Pharmaceuticals Inc. as lead sponsor.

NCT NCT01917630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01917630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study of the Efficacy and Safety of ALV003 Treatment in Symptomatic Celiac Disease Patients Maintained on a Gluten-Free Diet
Lead sponsor
Alvine Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
August 31, 2013
Completion date
June 30, 2015
Enrollment
500 (estimated)
Sites
88

Conditions

As the registry lists them; a condition with its own page is linked.

celiac disease